| Literature DB >> 31769173 |
Julián Nevado1,2, Karen S Ho3,4,5, Marcella Zollino6, Raquel Blanco7, César Cobaleda8, Christelle Golzio9, Isabelle Beaudry-Bellefeuille10, Sarah Berrocoso11, Jacobo Limeres12, Pilar Barrúz1, Candela Serrano-Martín12, Concetta Cafiero6, Ignacio Málaga7, Giuseppe Marangi6, Elena Campos-Sánchez8, Tania Moriyón-Iglesias10, Sorangui Márquez13, Leah Markham3, Hope Twede3, Amanda Lortz14, Lenora Olson4, Xiaoming Sheng4, Cindy Weng4, Edward Robert Wassman3, Tara Newcomb4, Edward Robert Wassman3, John C Carey4, Agatino Battaglia16, Eduardo López-Granados17, Damien Douglas18, Pablo Lapunzina1,2.
Abstract
"An International Meeting on Wolf-Hirschhorn Syndrome (WHS)" was held at The University Hospital La Paz in Madrid, Spain (October 13-14, 2017). One hundred and twenty-five people, including physicians, scientists and affected families, attended the meeting. Parent and patient advocates from the Spanish Association of WHS opened the meeting with a panel discussion to set the stage regarding their hopes and expectations for therapeutic advances. In keeping with the theme on therapeutic development, the sessions followed a progression from description of the phenotype and definition of therapeutic endpoints, to definition of genomic changes. These proceedings will review the major points of discussion.Entities:
Keywords: 4p-; WHS; antiepileptic drugs; hepatoadenomas; seizures
Year: 2019 PMID: 31769173 DOI: 10.1002/ajmg.a.61406
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.802